Ferinzhekt, 50 mg/ml 10 ml

Pherinject is a preparation of iron. It is a carboxymaltosate complex of multinuclear iron(III) hydroxide.

After parenteral administration the macromolecular complex is taken up by the reticulo-endothelial system and breaks down into iron and carboxymaltose.

The iron enters the bloodstream, where it binds to the transport protein transferrin.

The iron in complex with transferrin is transported to body cells, where it is used for the synthesis of hemoglobin, myoglobin and a large number of enzymes or accumulated as ferritin.

Indications

Iron deficiency anemia when oral iron supplements are ineffective or cannot be used.

The diagnosis must be confirmed by laboratory tests.

Pharmacological effect

Ferinject is an iron supplement. It is a carboxymaltose complex of polynuclear iron(III) hydroxide.

After parenteral administration, the macromolecular complex is captured by the reticuloendothelial system and breaks down into iron and carboxymaltose.

Iron enters the bloodstream, where it binds to the transport protein transferrin.

Iron, in combination with transferrin, is transported to the cells of the body, where it is used for the synthesis of hemoglobin, myoglobin and a large number of enzymes or accumulates in the form of ferritin.

Active ingredient

Iron carboxymaltose

Composition

1 ml. solution for intravenous administration contains:

active ingredient:

iron carboxymaltose 50 mg

Contraindications

anemia not associated with iron deficiency;
symptoms of iron overload or impaired iron utilization;
I trimester of pregnancy;
children under 14 years of age;
hypersensitivity to the components of the drug Ferinject.

The drug should be used with caution in case of liver failure, acute or chronic infectious diseases (possible inhibition of erythropoiesis), bronchial asthma, eczema, atopic allergies.

Side Effects

Allergic reactions: often – rash; uncommon – urticaria, hypersensitivity reactions, including anaphylactoid reactions.

From the nervous system: often – headache; dizziness; infrequently – paresthesia.

From the cardiovascular system: infrequently – decreased blood pressure, “flushes” of blood to the skin of the face.

From the respiratory system: rarely – shortness of breath.

From the digestive system: often – nausea, abdominal pain, diarrhea, constipation; uncommon – change in taste, vomiting, dyspepsia, flatulence.

From the musculoskeletal system: infrequently – myalgia, back pain, arthralgia.

General reactions: uncommon – fever, fatigue, chest pain, chills, feeling unwell, peripheral edema.

Local reactions: often – reactions at the injection site.

From the laboratory parameters: often – an increase in ALT in the blood serum, a transient decrease in the phosphate content in the blood serum; infrequently – increased activity of AST, GGT, LDH.

Overdose

Symptoms: Ferinject in quantities exceeding the body’s needs can cause iron overload, which manifests itself as symptoms of hemosiderosis. Determination of iron metabolism parameters such as serum ferritin and percentage of transferrin saturation can help in diagnosing excessive iron deposition in the body.

Treatment: symptomatic therapy. If necessary, chelate compounds (for example, deferoxamine) can be used.

Storage conditions

At a temperature not exceeding 30 °C, in the original packaging (do not freeze)

Shelf life

3 years

Manufacturer

IDT Biology GmbH, Germany